Exact Mass: 940.4668

Exact Mass Matches: 940.4668

Found 53 metabolites which its exact mass value is equals to given mass value 940.4668, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Amaranthussaponin III

3,5-dihydroxy-6-{[2-hydroxy-4,4,6a,6b,14b-pentamethyl-11-methylidene-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxane-2-carboxylic acid

C47H72O19 (940.4668)


Amaranthussaponin III is found in cereals and cereal products. Amaranthussaponin III is a constituent of Amaranthus hypochondriacus (princes feather). Constituent of Amaranthus hypochondriacus (princes feather). Amaranthussaponin III is found in cereals and cereal products.

   

Melilotussaponin O2

6-{[11-carboxy-4-(hydroxymethyl)-4,6a,6b,8a,11,14b-hexamethyl-9-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-5-({4,5-dihydroxy-3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl}oxy)-3,4-dihydroxyoxane-2-carboxylic acid

C47H72O19 (940.4668)


Melilotussaponin O2 is found in green vegetables. Melilotussaponin O2 is a constituent of Melilotus officinalis (sweet clover) Constituent of Melilotus officinalis (sweet clover). Melilotussaponin O2 is found in green vegetables.

   

PGP(18:2(9Z,11Z)/6 keto-PGF1alpha)

[(2S)-3-({[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-3-[(9Z,11Z)-octadeca-9,11-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C44H78O17P2 (940.4714)


PGP(18:2(9Z,11Z)/6 keto-PGF1alpha) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(18:2(9Z,11Z)/6 keto-PGF1alpha), in particular, consists of one chain of one 9Z,11Z-octadecadienoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(6 keto-PGF1alpha/18:2(9Z,11Z))

[(2S)-3-({[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-2-[(9Z,11Z)-octadeca-9,11-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C44H78O17P2 (940.4714)


PGP(6 keto-PGF1alpha/18:2(9Z,11Z)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(6 keto-PGF1alpha/18:2(9Z,11Z)), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 9Z,11Z-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(18:2(9Z,11Z)/TXB2)

[(2S)-3-({[(2R)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-3-[(9Z,11Z)-octadeca-9,11-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C44H78O17P2 (940.4714)


PGP(18:2(9Z,11Z)/TXB2) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(18:2(9Z,11Z)/TXB2), in particular, consists of one chain of one 9Z,11Z-octadecadienoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(TXB2/18:2(9Z,11Z))

[(2S)-3-({[(2R)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-2-[(9Z,11Z)-octadeca-9,11-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C44H78O17P2 (940.4714)


PGP(TXB2/18:2(9Z,11Z)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(TXB2/18:2(9Z,11Z)), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of 9Z,11Z-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(18:2(9Z,12Z)/6 keto-PGF1alpha)

[(2S)-3-({[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C44H78O17P2 (940.4714)


PGP(18:2(9Z,12Z)/6 keto-PGF1alpha) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(18:2(9Z,12Z)/6 keto-PGF1alpha), in particular, consists of one chain of one 9Z,12Z-octadecadienoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(6 keto-PGF1alpha/18:2(9Z,12Z))

[(2S)-3-({[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-2-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C44H78O17P2 (940.4714)


PGP(6 keto-PGF1alpha/18:2(9Z,12Z)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(6 keto-PGF1alpha/18:2(9Z,12Z)), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 9Z,12Z-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(18:2(9Z,12Z)/TXB2)

[(2S)-3-({[(2R)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-3-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C44H78O17P2 (940.4714)


PGP(18:2(9Z,12Z)/TXB2) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(18:2(9Z,12Z)/TXB2), in particular, consists of one chain of one 9Z,12Z-octadecadienoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(TXB2/18:2(9Z,12Z))

[(2S)-3-({[(2R)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-2-[(9Z,12Z)-octadeca-9,12-dienoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C44H78O17P2 (940.4714)


PGP(TXB2/18:2(9Z,12Z)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(TXB2/18:2(9Z,12Z)), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of 9Z,12Z-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

Acanjaposide A

Acanjaposide A

C47H72O19 (940.4668)


   

Sublanceoside F4

Sublanceoside F4

C47H72O19 (940.4668)


   
   

cynantratoside-E

cynantratoside-E

C47H72O19 (940.4668)


   

3-O-??-D-Galactopyranosyl-(1鈥樏傗垎2)-[??-D-xylopyranosyl(1鈥樏傗垎3)]-??-D-glucuronopyranosyl-gypsogenin

3-O-??-D-Galactopyranosyl-(1鈥樏傗垎2)-[??-D-xylopyranosyl(1鈥樏傗垎3)]-??-D-glucuronopyranosyl-gypsogenin

C47H72O19 (940.4668)


   
   

2alpha,3beta-dihydroxy-23-oxo-30-norolean-12,20(29)-dien-28-oic acid O-alpha-L-rhamnopyranosyl-(1?4)-O-beta-D-glucopyranosyl-(1?6)-beta-D-glucopyranosyl ester|akemisaponin K

2alpha,3beta-dihydroxy-23-oxo-30-norolean-12,20(29)-dien-28-oic acid O-alpha-L-rhamnopyranosyl-(1?4)-O-beta-D-glucopyranosyl-(1?6)-beta-D-glucopyranosyl ester|akemisaponin K

C47H72O19 (940.4668)


   

akemisaponin G

akemisaponin G

C47H72O19 (940.4668)


   

3-(O-beta-D-glucopyranosyl(1?3)-alpha-L-arabinopyranosyl)-urs-12,18-diene-24,28-dioic acid 28-O-beta-D-glucopyranoside|ilexsaponin D

3-(O-beta-D-glucopyranosyl(1?3)-alpha-L-arabinopyranosyl)-urs-12,18-diene-24,28-dioic acid 28-O-beta-D-glucopyranoside|ilexsaponin D

C47H72O19 (940.4668)


   

bodinone glycoside

bodinone glycoside

C47H72O19 (940.4668)


   

13beta-hydroxycynajapogenin A 3-O-beta-D-glucopyranosyl-(1->4)-beta-D-cymaropyranosyl-(1->4)-alpha-L-diginopyranosyl-(1->4)-beta-D-cymaropyranoside|cynanoside Q1

13beta-hydroxycynajapogenin A 3-O-beta-D-glucopyranosyl-(1->4)-beta-D-cymaropyranosyl-(1->4)-alpha-L-diginopyranosyl-(1->4)-beta-D-cymaropyranoside|cynanoside Q1

C47H72O19 (940.4668)


   

Amaranthussaponin III

3,5-dihydroxy-6-{[2-hydroxy-4,4,6a,6b,14b-pentamethyl-11-methylidene-8a-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxane-2-carboxylic acid

C47H72O19 (940.4668)


   

PGP(18:2(9Z,11Z)/TXB2)

PGP(18:2(9Z,11Z)/TXB2)

C44H78O17P2 (940.4714)


   

PGP(TXB2/18:2(9Z,11Z))

PGP(TXB2/18:2(9Z,11Z))

C44H78O17P2 (940.4714)


   

PGP(18:2(9Z,12Z)/TXB2)

PGP(18:2(9Z,12Z)/TXB2)

C44H78O17P2 (940.4714)


   

PGP(TXB2/18:2(9Z,12Z))

PGP(TXB2/18:2(9Z,12Z))

C44H78O17P2 (940.4714)


   

PGP(18:2(9Z,11Z)/6 keto-PGF1alpha)

PGP(18:2(9Z,11Z)/6 keto-PGF1alpha)

C44H78O17P2 (940.4714)


   

PGP(6 keto-PGF1alpha/18:2(9Z,11Z))

PGP(6 keto-PGF1alpha/18:2(9Z,11Z))

C44H78O17P2 (940.4714)


   

PGP(18:2(9Z,12Z)/6 keto-PGF1alpha)

PGP(18:2(9Z,12Z)/6 keto-PGF1alpha)

C44H78O17P2 (940.4714)


   

PGP(6 keto-PGF1alpha/18:2(9Z,12Z))

PGP(6 keto-PGF1alpha/18:2(9Z,12Z))

C44H78O17P2 (940.4714)


   

8-{[5-({4-hydroxy-5-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

8-{[5-({4-hydroxy-5-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

C47H72O19 (940.4668)


   

3-o-β-d-galactopyranosyl-(1→2)-[β-d-xylo-pyranosyl(1→3)]-β-d-glucuronopyranosyl-gypsogenin

NA

C47H72O19 (940.4668)


{"Ingredient_id": "HBIN009149","Ingredient_name": "3-o-\u03b2-d-galactopyranosyl-(1\u21922)-[\u03b2-d-xylo-pyranosyl(1\u21923)]-\u03b2-d-glucuronopyranosyl-gypsogenin","Alias": "NA","Ingredient_formula": "C47H72O19","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "8073","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

acanjaposide a

NA

C47H72O19 (940.4668)


{"Ingredient_id": "HBIN014323","Ingredient_name": "acanjaposide a","Alias": "NA","Ingredient_formula": "C47H72O19","Ingredient_Smile": "CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OCC3C(C(C(C(O3)OC(=O)C45CCC(=C)CC4C6=CCC7C8(CCC(C(C8CCC7(C6(CC5)C)C)(C)C(=O)O)O)C)O)O)O)CO)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "64","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(2s,4as,4br,6r,7r,10ar)-2,6-dihydroxy-7-{[(2s,4s,5r,6r)-4-methoxy-5-{[(2s,4s,5r,6s)-4-methoxy-5-{[(2s,4s,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4b-methyl-2-(2-methylfuran-3-yl)-4,4a,5,6,7,8,10,10a-octahydro-3h-phenanthren-1-one

(2s,4as,4br,6r,7r,10ar)-2,6-dihydroxy-7-{[(2s,4s,5r,6r)-4-methoxy-5-{[(2s,4s,5r,6s)-4-methoxy-5-{[(2s,4s,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4b-methyl-2-(2-methylfuran-3-yl)-4,4a,5,6,7,8,10,10a-octahydro-3h-phenanthren-1-one

C47H72O19 (940.4668)


   

(4s,5r,8s,13r,19r,22r)-8-{[(2r,4r,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2r,4r,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

(4s,5r,8s,13r,19r,22r)-8-{[(2r,4r,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2r,4r,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

C47H72O19 (940.4668)


   

6-{[3a-carboxy-6,6,9a,11a-tetramethyl-1-(6-methylhept-5-en-2-yl)-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-({6-carboxy-3,5-dihydroxy-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-4,5-dihydroxyoxane-2-carboxylic acid

6-{[3a-carboxy-6,6,9a,11a-tetramethyl-1-(6-methylhept-5-en-2-yl)-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-({6-carboxy-3,5-dihydroxy-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-4,5-dihydroxyoxane-2-carboxylic acid

C47H72O19 (940.4668)


   

(2s,3r,4s,5r,6r)-2-{[(2s,3s,4r,6s)-6-{[(2r,3s,4s,6s)-4-hydroxy-6-{[(2r,3r,4s,6s)-6-{[(1r,4r,5r,7r,8r,16s,19s,22r)-7-hydroxy-5,19-dimethyl-15,18,20-trioxahexacyclo[14.5.1.0¹,¹⁴.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-10,13-dien-8-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3r,4s,5r,6r)-2-{[(2s,3s,4r,6s)-6-{[(2r,3s,4s,6s)-4-hydroxy-6-{[(2r,3r,4s,6s)-6-{[(1r,4r,5r,7r,8r,16s,19s,22r)-7-hydroxy-5,19-dimethyl-15,18,20-trioxahexacyclo[14.5.1.0¹,¹⁴.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-10,13-dien-8-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C47H72O19 (940.4668)


   

(2r,4as,6br,8ar,12ar,12bs,14as,14bs)-4a-({[(2s,3r,4s,5s,6r)-6-({[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}carbonyl)-2,9,9,12a,14b-pentamethyl-10-oxo-1,3,4,5,6b,7,8,8a,11,12,12b,13,14,14a-tetradecahydropicene-2-carboxylic acid

(2r,4as,6br,8ar,12ar,12bs,14as,14bs)-4a-({[(2s,3r,4s,5s,6r)-6-({[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}carbonyl)-2,9,9,12a,14b-pentamethyl-10-oxo-1,3,4,5,6b,7,8,8a,11,12,12b,13,14,14a-tetradecahydropicene-2-carboxylic acid

C47H72O19 (940.4668)


   

(4s,5r,8s,13s,16s,19r,22r)-8-{[(2r,4r,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2s,4r,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

(4s,5r,8s,13s,16s,19r,22r)-8-{[(2r,4r,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2s,4r,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

C47H72O19 (940.4668)


   

(2s,3r,4s,5s,6r)-2-{[(2s,3s,4r,6s)-6-{[(2r,3s,4s,6s)-4-hydroxy-6-{[(2r,3r,4s,6s)-6-{[(1r,4r,5r,7r,8r,16s,19s,22r)-7-hydroxy-5,19-dimethyl-15,18,20-trioxahexacyclo[14.5.1.0¹,¹⁴.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-10,13-dien-8-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3r,4s,5s,6r)-2-{[(2s,3s,4r,6s)-6-{[(2r,3s,4s,6s)-4-hydroxy-6-{[(2r,3r,4s,6s)-6-{[(1r,4r,5r,7r,8r,16s,19s,22r)-7-hydroxy-5,19-dimethyl-15,18,20-trioxahexacyclo[14.5.1.0¹,¹⁴.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-10,13-dien-8-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C47H72O19 (940.4668)


   

8a-({[6-({[3,4-dihydroxy-6-(hydroxymethyl)-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}carbonyl)-3-hydroxy-4,6a,6b,14b-tetramethyl-11-methylidene-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

8a-({[6-({[3,4-dihydroxy-6-(hydroxymethyl)-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}carbonyl)-3-hydroxy-4,6a,6b,14b-tetramethyl-11-methylidene-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C47H72O19 (940.4668)


   

4a-({[6-({[3,4-dihydroxy-6-(hydroxymethyl)-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}carbonyl)-2,9,9,12a,14b-pentamethyl-10-oxo-1,3,4,5,6b,7,8,8a,11,12,12b,13,14,14a-tetradecahydropicene-2-carboxylic acid

4a-({[6-({[3,4-dihydroxy-6-(hydroxymethyl)-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]oxan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}carbonyl)-2,9,9,12a,14b-pentamethyl-10-oxo-1,3,4,5,6b,7,8,8a,11,12,12b,13,14,14a-tetradecahydropicene-2-carboxylic acid

C47H72O19 (940.4668)


   

(3r,4r,4ar,6ar,6br,8as,12as,14as,14bs)-8a-({[(2r,3s,4r,5r,6s)-6-({[(2s,3s,4s,5r,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}carbonyl)-3-hydroxy-4,6a,6b,14b-tetramethyl-11-methylidene-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

(3r,4r,4ar,6ar,6br,8as,12as,14as,14bs)-8a-({[(2r,3s,4r,5r,6s)-6-({[(2s,3s,4s,5r,6s)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2r,3s,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}carbonyl)-3-hydroxy-4,6a,6b,14b-tetramethyl-11-methylidene-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C47H72O19 (940.4668)


   

(2s,3s,4r,5r,6r)-6-{[(1r,3as,5ar,7s,9as,11ar)-3a-carboxy-6,6,9a,11a-tetramethyl-1-[(2r)-6-methylhept-5-en-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-{[(2r,3r,4s,5r,6s)-6-carboxy-3,5-dihydroxy-4-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid

(2s,3s,4r,5r,6r)-6-{[(1r,3as,5ar,7s,9as,11ar)-3a-carboxy-6,6,9a,11a-tetramethyl-1-[(2r)-6-methylhept-5-en-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-{[(2r,3r,4s,5r,6s)-6-carboxy-3,5-dihydroxy-4-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid

C47H72O19 (940.4668)


   

(4s,5r,8s,13r,16s,19r,22r)-8-{[(2r,4r,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2r,4r,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

(4s,5r,8s,13r,16s,19r,22r)-8-{[(2r,4r,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2r,4r,5r,6r)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

C47H72O19 (940.4668)


   

(2s,3r,4r,5r,6s)-6-{[(1r,3as,5ar,7s,9as,11ar)-3a-carboxy-6,6,9a,11a-tetramethyl-1-[(2r)-6-methylhept-5-en-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-{[(2s,3r,4s,5r,6s)-6-carboxy-3,5-dihydroxy-4-{[(2r,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid

(2s,3r,4r,5r,6s)-6-{[(1r,3as,5ar,7s,9as,11ar)-3a-carboxy-6,6,9a,11a-tetramethyl-1-[(2r)-6-methylhept-5-en-2-yl]-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-{[(2s,3r,4s,5r,6s)-6-carboxy-3,5-dihydroxy-4-{[(2r,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-4,5-dihydroxyoxane-2-carboxylic acid

C47H72O19 (940.4668)


   

(4s,5r,8s,13r,16s,19r,22r)-8-{[(2r,4r,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2s,4r,5s,6s)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

(4s,5r,8s,13r,16s,19r,22r)-8-{[(2r,4r,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2s,4r,5s,6s)-4-methoxy-6-methyl-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,19-dimethyl-15,18,20-trioxapentacyclo[14.5.1.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-1(21),10-dien-14-one

C47H72O19 (940.4668)


   

6-[(8a-carboxy-4-formyl-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl)oxy]-3-hydroxy-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxane-2-carboxylic acid

6-[(8a-carboxy-4-formyl-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl)oxy]-3-hydroxy-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxane-2-carboxylic acid

C47H72O19 (940.4668)


   

2,6-dihydroxy-7-{[4-methoxy-5-({4-methoxy-5-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-6-methyloxan-2-yl]oxy}-4b-methyl-2-(2-methylfuran-3-yl)-4,4a,5,6,7,8,10,10a-octahydro-3h-phenanthren-1-one

2,6-dihydroxy-7-{[4-methoxy-5-({4-methoxy-5-[(4-methoxy-6-methyl-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-6-methyloxan-2-yl]oxy}-4b-methyl-2-(2-methylfuran-3-yl)-4,4a,5,6,7,8,10,10a-octahydro-3h-phenanthren-1-one

C47H72O19 (940.4668)


   

2-({6-[(4-hydroxy-6-{[6-({7-hydroxy-5,19-dimethyl-15,18,20-trioxahexacyclo[14.5.1.0¹,¹⁴.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-10,13-dien-8-yl}oxy)-4-methoxy-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl)oxy]-4-methoxy-2-methyloxan-3-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

2-({6-[(4-hydroxy-6-{[6-({7-hydroxy-5,19-dimethyl-15,18,20-trioxahexacyclo[14.5.1.0¹,¹⁴.0⁴,¹³.0⁵,¹⁰.0¹⁹,²²]docosa-10,13-dien-8-yl}oxy)-4-methoxy-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl)oxy]-4-methoxy-2-methyloxan-3-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol

C47H72O19 (940.4668)


   

(2s,3s,4s,5r,6r)-6-{[(3s,4s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4-formyl-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3-hydroxy-5-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxane-2-carboxylic acid

(2s,3s,4s,5r,6r)-6-{[(3s,4s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4-formyl-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3-hydroxy-5-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxane-2-carboxylic acid

C47H72O19 (940.4668)


   

(2s,3s,4s,5r,6r)-6-{[(2s,3r,4ar,6ar,6bs,8as,12as,14ar,14br)-2-hydroxy-4,4,6a,6b,14b-pentamethyl-11-methylidene-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,5-dihydroxy-4-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxane-2-carboxylic acid

(2s,3s,4s,5r,6r)-6-{[(2s,3r,4ar,6ar,6bs,8as,12as,14ar,14br)-2-hydroxy-4,4,6a,6b,14b-pentamethyl-11-methylidene-8a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,5-dihydroxy-4-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxane-2-carboxylic acid

C47H72O19 (940.4668)


   

(3s,4s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-({[(2s,3r,4s,5s,6r)-6-({[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}carbonyl)-3-hydroxy-4,6a,6b,14b-tetramethyl-11-methylidene-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

(3s,4s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-({[(2s,3r,4s,5s,6r)-6-({[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-2-yl]oxy}methyl)-3,4,5-trihydroxyoxan-2-yl]oxy}carbonyl)-3-hydroxy-4,6a,6b,14b-tetramethyl-11-methylidene-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4-carboxylic acid

C47H72O19 (940.4668)